Drugs / NYCE T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03399448 | Sep 2018 → Feb 2020 | melanoma, myxoid/round cell liposarcoma, plasma cell myeloma, synovial sarcoma | University of Pennsylvania | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NYCE T Cells | “Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1...” NCT03399448 ↗ |
| Action | Inhibit | “Two genes encoding the endogenous T cell receptor (TCR) chains, TCRα (TRAC) and TCRβ (TRBC), were deleted in T cells to reduce TCR mispairing and to enhance the expression of a...” PMID 32029687 ↗ Feb 2020 |
| Target | PDCD1 | “Removal of a third gene encoding programmed cell death protein 1 (PD-1; PDCD1), was performed to improve antitumor immunity.” PMID 32029687 ↗ Feb 2020 |
| Target | TRAC | “Two genes encoding the endogenous T cell receptor (TCR) chains, TCRα (TRAC) and TCRβ (TRBC), were deleted in T cells to reduce TCR mispairing and to enhance the expression of a...” PMID 32029687 ↗ Feb 2020 |